Back to top

cell-therapy: Archive

Zacks Equity Research

CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

BIIBNegative Net Change VRTXPositive Net Change FOLDPositive Net Change CRSPPositive Net Change

Zacks Equity Research

CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?

On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.

REGNNegative Net Change PFEPositive Net Change VRTXPositive Net Change CRSPPositive Net Change